MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Takeda Pharmaceutical Co Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

14.89 0.2

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.86

Max

14.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-68B

24B

Pardavimai

-32B

1.1T

P/E

Sektoriaus vid.

34.581

63.778

Pelnas, tenkantis vienai akcijai

0.048

Dividendų pajamingumas

4.39

Pelno marža

2.079

Darbuotojai

49,281

EBITDA

-4.3B

380B

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.39%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

47B

Ankstesnė atidarymo kaina

14.69

Ankstesnė uždarymo kaina

14.89

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-01-30 11:02; UTC

Uždarbis

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

2025-01-30 07:53; UTC

Uždarbis

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

2025-01-28 00:03; UTC

Karštos akcijos

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

2024-10-31 07:27; UTC

Uždarbis

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

2024-10-31 06:44; UTC

Uždarbis

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

2024-07-31 07:19; UTC

Uždarbis

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

2024-07-31 06:29; UTC

Uždarbis

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

2024-06-17 13:34; UTC

Pagrindinės rinkos jėgos

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

2024-05-13 11:26; UTC

Pagrindinės rinkos jėgos

AC Immunity Shares Soar on Exclusive License Deal with Takeda

2024-05-09 07:37; UTC

Uždarbis

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

2024-05-09 07:08; UTC

Uždarbis

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

2025-01-30 07:12; UTC

Uždarbis

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

2025-01-30 07:08; UTC

Uždarbis

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

2025-01-30 06:42; UTC

Uždarbis

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

2025-01-30 06:40; UTC

Uždarbis

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

2025-01-30 06:36; UTC

Uždarbis

Takeda: to Discontinue Soticlestat Development Program

2025-01-30 06:34; UTC

Uždarbis

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

2025-01-30 06:32; UTC

Uždarbis

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

2025-01-30 06:31; UTC

Uždarbis

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical Sees FY Net Y118.00B

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical Sees FY Net Y118.00B

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical Raises FY Dividend to Y196.00

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

2025-01-30 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Akcijų palyginimas

Kainos pokytis

Takeda Pharmaceutical Co Ltd ADR Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.9 / 15.155Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.